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Abstract
Background: In non-pregnant adults, the incidence of invasive Group B Streptococcus (GBS) disease is continuously
increasing. Elderly and immunocompromised persons are at increased risk of infection. GBS commonly colonizes
the vaginal tract, though data on colonization in the elderly are scarce. It is unknown whether the prevalence of
GBS colonization is increasing in parallel to the observed rise of invasive infection. We conducted a three-year
(2017–2019) prospective observational cross-sectional study in two teaching hospitals in Switzerland to determine
the rate of GBS vaginal colonization in women over 60 years and i) to compare the proportions of known risk
factors associated with invasive GBS diseases in colonized versus non-colonized women and ii) to evaluate the
presence of GBS clusters with specific phenotypic and genotypic patterns in this population.
Methods: GBS screening was performed by using vaginal swabs collected during routine examination from
women willing to participate in the study and to complete a questionnaire for risk factors. Isolates were
characterized for antibiotic resistance profile, serotype and sequence type (ST).
Results: The GBS positivity rate in the elderly was 17% (44/255 positive samples), and similar to the one previously
reported in pregnant women (around 20%). We could not find any association between participants’ characteristics,
previously published risk factors and GBS colonization. All strains were susceptible to penicillin, 22% (8/36) were not
susceptible to erythromycin, 14% (5/36) were not susceptible to clindamycin and 8% (3/36) showed inducible
clindamycin resistance. Both M and L phenotypes were each detected in one isolate. The most prevalent serotypes
were III (33%, 12/36) and V (31%, 11/36). ST1 and ST19 accounted for 11% of isolates each (4/36); ST175 for 8% (3/
36); and ST23, ST249 and ST297 for 6% each (2/36). Significantly higher rates of resistance to macrolides and
clindamycin were associated with the ST1 genetic background of ST1.
Conclusions: Our findings indicate a similar colonization rate for pregnant and elderly women.
Trial registration: Current Controlled Trial ISRCTN15468519; 06/01/2017
Keywords: Group B Streptococcus, Streptococcus agalactiae, Colonization, Elderly women, Postmenopausal women
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: parham.sendi@ifik.unibe.ch
1Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3010
Bern, Switzerland
5Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel
and University of Basel, Basel, Switzerland
Full list of author information is available at the end of the article
Baldan et al. BMC Infectious Diseases          (2021) 21:408 
https://doi.org/10.1186/s12879-021-06102-x
Background
Group B Streptococcus (GBS, Streptococcus agalactiae)
is a pathobiont frequently found in the normal micro-
biota of the gastrointestinal and vaginal tracts of women
[1, 2]. GBS can cause life-threatening infections in neo-
nates, with maternal colonization being the principal
route of transmission. In non-pregnant adults, the inci-
dence of infection is continuously increasing [3, 4]. Eld-
erly and immunocompromised persons with underlying
conditions, such as diabetes mellitus and cancer, are at
increased risk of invasive GBS disease [4–6]. A Danish
study showed that from 2005 to 2018, the incidence of
invasive GBS in adults aged 65–74 years increased from
3.23 to 8.34 per 100,000, and in adults over 75 years
from 6.85 to 16.01 per 100,000 [7]. Their finding aligns
with data from Iceland, Finland, Norway, England and
Wales, Canada, and other countries [8–12]. Skin and
soft-tissue infection, primary bacteraemia and urinary
tract infection are the most frequent clinical manifesta-
tions of invasive GBS disease in the elderly [13, 14].
Most studies have investigated the prevalence of GBS
colonization in pregnant women, only a few focusing on
non-pregnant adults [13, 15]. Vaginal colonization in
pregnant women worldwide ranges between 5 and 30%–
35%, with an average estimate of approximately 20% [14,
16]. In contrast, little is known about the GBS
colonization rate in women older than 60 years of age. It
is unknown whether the prevalence of GBS colonization
is increasing in parallel to the observed rise of invasive
infection. The site of GBS colonization could potentially
be the source of invasive infection, underscoring the im-
portance to investigating the colonization rate in this pa-
tient population.
We present here the results of a prospective observa-
tional cross-sectional study in which we aimed to deter-
mine the vaginal colonization rate in women over the
age of 60 in two teaching hospitals in Switzerland. Sec-
ondary objectives of the study were to compare the pro-
portions of known risk factors associated with invasive
GBS diseases in colonized versus non-colonized women
and to evaluate the presence of clusters with specific
phenotypic and genotypic patterns in GBS strains iso-
lated in our population.
Methods
Study design and participants’ data
Women presenting at the outpatient clinic of two cen-
tres (Bern and Basel University hospitals) for a routine
vaginal examination between January 2017 and Decem-
ber 2019 were screened for eligibility. Participants to be
included in the study had to be ≥60 years old and cap-
able of reading and understanding the patient informa-
tion sheet and giving voluntary written consent to
participate in the study, in which a vaginal swab would
be collected during their routine gynaecological examin-
ation and cultured for the presence of GBS. In addition,
participants were asked to complete a short question-
naire to obtain data regarding ethnicity, current or prior
medical conditions, menstrual history and sexual history
(Supplementary Material). Patient consent, study infor-
mation and questionnaires were available in four lan-
guages (German, French, Italian and English). The swab
and the questionnaire were coded to protect partici-
pants’ identifiable data and privacy, according to the ap-
proved study protocol (trial registration no. ISRC
TN15468519). The study was approved by the local eth-
ical committee (Kantonale Ethikkommission-Bern:
2016–01669).
GBS culture and characterization
GBS screening was carried out with the same method-
ology throughout the whole study period. Isolation of
the strain from vaginal samples was performed by
growth in an enrichment medium (Todd–Hewitt broth)
followed by subculture on a selective GBS chromagar
plate (StrepB, CHROMagarTM, Paris, France). Identified
colonies were subjected to MALDI-TOF mass
spectrometry.
GBS isolates were further characterized at the pheno-
typic and genotypic level to determine the antibiotic re-
sistance profile, the capsular serotype and the clone
sequence type (ST). The minimal inhibitory concentra-
tions (MICs) for penicillin, clindamycin and erythro-
mycin were determined by E-test (bioMérieux, Marcy
l’Etoile, France) and interpreted according to CLSI
guidelines [17]. Detection of the macrolide-lincosamide-
streptogramin B (MLSB) resistance phenotype was
assessed by double disk diffusion test [18, 19]. Capsular
serotyping was performed by use of a rapid latex agglu-
tination test and polymerase chain reaction analysis, as
previously described [20, 21] Sequence type was deter-
mined by multilocus sequence typing as described else-
where (https://pubmlst.org/sagalactiae/). One sample per
patient was included in the analysis. In the case of mul-
tiple sampling from the same participant, only the swab
obtained at the first visit was analysed.
Data analysis
Questionnaire and microbiology data were recorded in
an electronic database designed with REDCap software
(Research Electronic Data CAPture). Significant associa-
tions between participants’ characteristics/risk factors,
GBS carrier status, GBS antibiotic resistance profiles, se-
rotypes and sequence types were investigated. In the
case of missing answers per single question, the denom-
inator for each analysis was adapted accordingly. Graph-
Pad Prism 8.0 was used for statistical analysis. The
association between age variables and a positive GBS
Baldan et al. BMC Infectious Diseases          (2021) 21:408 Page 2 of 8
result was investigated by using the Mann-Whitney test.
Differences in the prevalence of risk factors between
GBS-positive and GBS-negative groups were assessed by
contingency tables and the chi-square test, or by Fisher’s
exact probability test if the frequency was less than 5.
For direct comparisons, distribution analyses were also
performed by using the chi-square test, Fisher’s exact
test or Cochran-Armitage trend analysis. A two-tailed p-
value of ≤0.05 was considered significant.
Results
During the study period, 263 samples were collected
from a total of 259 patients from the two centres, as
shown in Fig. 1. Four samples were excluded from ana-
lysis, as they were obtained from the same patients dur-
ing a second clinic visit. Another four were excluded
because the samples could not be cultured. Thus, a total
of 255 unique samples were included in the study.
Overall, the GBS positivity rate was 17% (44/255 posi-
tive samples), which was similar in both study sites (Bern
centre: 18%, 35/199; Basel centre: 16%, 9/56). The results
of the questionnaire data, including participants’ demo-
graphic characteristics and risk factors for GBS
colonization, were analysed overall and divided by GBS
carrier status, a summary of which is shown in Table 1.
No significant associations were found between the par-
ticipants’ demographic characteristics, medical history,
menstrual history, sexual activity and GBS status.
Of the 44 swabs that tested positive, 36 GBS isolates
were available for phenotypic and genotypic
characterization (Fig. 1). The results are presented in
Table 2. All 36 GBS isolates were susceptible to penicil-
lin, with an MIC ranging between 0.032 and 0.094 mg/L.
Eight GBS isolates (22%) were not susceptible to
erythromycin, and three of them (3/8, 37.5%) had a MIC
of ≥256 mg/L. Five isolates (14%) were not susceptible to
clindamycin, four of them (4/5, 80%) with a MIC of
≥256 mg/L and one with a MIC of 1.5 mg/L. In addition,
three GBS isolates (8%) that were considered clindamy-
cin susceptible by E-test (MIC 0.19 mg/L) showed the
MLSB phenotype when tested by the double disk diffu-
sion test, indicating inducible clindamycin resistance.
Hence, eight (22%) GBS isolates were considered non-
susceptible to clindamycin. Twenty-seven GBS isolates
(75%) were susceptible to both clindamycin and
erythromycin.
One GBS isolate belonging to capsular serotype Ia and
ST624 (3%) showed an M phenotype, with erythromycin
resistance only (MIC 4mg/L). One GBS isolate assigned
to capsular serotype III and ST19 (3%) displayed the L
phenotype, being resistant to clindamycin only (MIC 1.5
mg/L).
Capsular serotyping showed that the most prevalent
serotypes were III (33%, 12/36), V (31%, 11/36) and Ia
(17%, 6/36). Multilocus sequence typing analysis showed
that the most common sequence types were ST1 and
Fig. 1 GBS Cite study flowchart
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ST19, accounting for four isolates each (11%); ST175
with three isolates (8%); and ST23, ST249 and ST297
with two isolates each (6%). Five strains could not be
assigned to a sequence type (no exact match, 14%), while
the remaining 14 isolates belonged to unique sequence
types, including one to ST17 and capsular serotype III.
Compared with non-ST1 isolates, ST1 (serotype V)
isolates were significantly associated with resistance to
Table 1 Participants’ demographic characteristics and risk factors for GBS acquisition overall and by GBS carrier status
Participants’ characteristics/risk factors Overall (n =
255)
GBS positive (n =
44)




Mean age at enrolment (years, SD) 68 (6) 68 (5) 69 (6) 0.59
Minimum-maximum age (years) 69–98 60–84 60–98 Na
Participants’ origin 0.46*
Swiss (%) 205/239 (86%) 38/42 (90%) 167/197 (85%)
Other (%) 34/239 (14%) 4/42 (10%) 30/197 (15%)
Not answered (%) 16/255 (6%) 2/44 (5%) 14/255 (7%) Na
Medical history
No. of participants with diabetes (%) 20/254 (8%) 3/44 (7%) 17/210 (8%) > 0.99*
No. of participants with liver disease (%) 7/253 (3%) 0/44 (0%) 7/209 (3%) 0.60*
No. of participants with history of stroke (%) 6/253 (2%) 1/44 (2%) 5/209 (2%) > 0.99*
No. of participants with bladder weakness (%) 84/246 (34%) 10/43 (23%) 74/203 (36%) 0.09
No. of participants with history of cancer (%) 43/251 (17%) 9/44 (20%) 34/207 (16%) 0.51
No. of participants still receiving cancer treatment (%) 17/39 (44%) 4/9 (44%) 13/30 (43%) > 0.99*
Menstruation
Mean age of first menstruation (years, SD) 14 (2) 14 (2) 14 (2) 0.97
Not answered 14/255 1/44 13/211 Na
Mean age of menopause (years, SD) 49 (7) 48 (8) 49 (7) 0.69
Not answered 25/255 2/44 23/211 Na
Sexual activity
No. of sexual partners during life 0.73§/
0.80°
1 or less (%) 77/247 (31%) 13/42 (31%) 64/205 (31%) 0.97
2 or 3 (%) 80/247 (32%) 14/42 (33%) 66/205 (32%) 0.88
3 or 4 (%) 42/247 (17%) 5/42 (12%) 37/205 (18%) 0.33
5 or more (%) 48/247 (20%) 10/42 (24%) 38/205 (19%) 0.43
Not answered (%) 8/255 (3%) 2/44 (4%) 6/211 (3%) Na
No. of participants with a new sexual partner in the last few months
before enrolment
11/255 (4%) 1/44 (2%) 10/211 (5%) 0.69*
No. of participants’ sexual encounters in the 6 months before enrolment 0.98§*/
0.65°
1 or less (%) 141/235 (60%) 24/41 (59%) 117/194 (60%) 0.83
2 or 3 (%) 15/235 (6%) 2/41 (4%) 13/194 (7%) > 0.99*
3 or 4 (%) 18/235 (8%) 3/41 (7%) 15/194 (8%) > 0.99*
At least once per month (%) 31/235 (13%) 6/41 (15%) 25/194 (13%) 0.76
At least once per week (%) 30/235 (13%) 6/41 (15%) 24/194 (12%) 0.69
Not answered (%) 20/255 (8%) 3/44 (7%) 17/211 (8%) Na
Association between age variables and GBS status was investigated by using the Mann-Whitney test; association between other risk factors and GBS status was
assessed by using the chi-square test or Fisher’s exact test (indicated by *); distribution analysis was also performed by using the chi-square test (indicated by §),
Fisher’s exact test (*) or Cochran-Armitage trend analysis (°). In each analysis, the denominator includes only participants who provided the information;
participants who did not answer the question were excluded. SD Standard deviation, Na Not applicable
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both clindamycin and erythromycin (p = 0.0129, when
considering constitutive resistance only; p = 0.0008,
when also including inducible clindamycin resistance)
and to the MLSB phenotype (p = 0.0060, Table 2).
This association was based on small absolute numbers
(n < 5).
Discussion
The number of invasive GBS infections in the elderly
population is continuously increasing [5], but the reason
for this phenomenon is unclear. In Denmark, between
2005 and 2018 the incidence of invasive GBS in adults
above the age of 65 years old increased more than two-
fold (from 3.23 to 8.34 per 100,000). Similar trends have
been reported in other countries [8–12]. The prevalence
of comorbidities that increase in parallel with age or an
increase in GBS colonization have been discussed as po-
tential contributing factors. Although the prevalence of
GBS colonization in pregnant women has been investi-
gated in numerous studies, with an average estimate
around 20%, the prevalence in the elderly population –
notably a group with increasing invasive GBS infections
– is unknown. The GBS colonization rate is associated
with sexual experience and activity [22, 23]. Considering
that sexual activity in older people can change over time
[24] and may have increased in recent decades, we
aimed to determine the vaginal GBS colonization rate in
elderly women. Our study showed a prevalence of GBS
colonization of 17% in postmenopausal women (mean
age, 68 years), similar to that reported by Moltó-Garcia
et al. (17.8%) in Spain [25]. Edwards et al. reported a
colonization rate of 21.7% in 254 healthy elderly partici-
pants (mean age, 73 years) in 2005 [15]. Kaplan et al.
found a prevalence of GBS colonization of 12% among
167 elderly home residents (median age, 84 years) in
1983 [26]. These data indicate that the GBS colonization
rate in pregnant women and healthy elderly adults is
similar [16].
All GBS isolates preserved susceptibility to penicillin.
However, compared with our previous study conducted
on GBS isolates from pregnant women tested between
2009 and 2010 in the same geographical area, we ob-
served a higher proportion of isolates that were non-
susceptible to erythromycin (22% vs 14.6%), to clindamy-
cin (14% vs 8.2%), and to both clindamycin and erythro-
mycin (11% vs 7.7%) and that displayed inducible
clindamycin resistance (8% vs 5.8%) [20]. However, a sci-
entific comparison is not possible, because no longitu-
dinal data were obtained. Moltó-Garcia et al. reported a
similar resistance rate to erythromycin (23.4%) among
their GBS samples collected between 2011 and 2012. Al-
though they detected a higher prevalence of constitutive
clindamycin resistance (20.6%), they observed the MLSB
phenotype in only 0.9% of their strains. Increasing trends





Penicillin susceptible 36/36 (100%)
Clindamycin susceptiblea 28/36 (78%)
Clindamycin non-susceptibleb 8/36 (22%)
Erythromycin susceptible 28/36 (78%)
Erythromycin non-susceptible 8/36 (22%)
MLSB phenotype (inducible clindamycin resistance) 3/36 (8%)
L phenotype (clindamycin resistant, erythromycin
susceptible)
1/36 (3%)
M phenotype (clindamycin susceptible, erythromycin
resistant)
1/36 (3%)
Clindamycin + Erythromycin non-susceptiblea 4/36 (11%)
Clindamycin + Erythromycin non-susceptibleb 7/36 (19%)
Serotyping
Serotype III 12/36 (33%)
Serotype V 11/36 (31%)
Serotype Ia 6/36 (17%)
Serotype Ib 2/36 (5%)
Serotype II 2/36 (5%)
Serotype IV 2/36 (5%)
Serotype VI 1/36 (3%)
Multilocus sequence typing







Other STs 14/36 (38%)
Phenotype association with genotype










MLSB phenotype negative/positive p = 0.0060
ST1 0/2
Non-ST1 29/1
MLSB Macrolide-lincosamide-streptogramin A, ST Sequence type as
determined by multilocus sequence typing
aExcluding isolates showing inducible clindamycin resistance by double
disk diffusion test
bIncluding isolates showing inducible clindamycin resistance
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of resistance were also reported elsewhere [7–11, 25,
27]. It is possible that elderly individuals were exposed
to antibiotics more frequently than were pregnant
women, and hence, GBS isolates display a higher resist-
ance rate. However, we did not make such a comparison
in our study.
We found one GBS isolate with L phenotype (clinda-
mycin resistant but erythromycin susceptible). This
phenotype is rare and may occur via the inactivation of
lincosamide-specific nucleotidyl-transferases encoded by
lnu genes [28]. Alternatively, this unusual mechanism of
resistance may also be mediated by the ABC transporter,
encoded by lsaC genes, and be responsible for cross-
resistance to streptogramin A (LSA phenotype) and
pleuromutilins (LSAP phenotype) [29, 30]. Recently,
there have been increasing reports of such a phenotype
in the United States, Europe, China, Korea and other
countries, with a prevalence ranging from 0.26% in Italy
to 15.9% in Korea [31–34]. This phenotype was detected
in one of the most common clones circulating world-
wide, ST19. This observation is worrisome because clin-
damycin is a frequently used alternative in patients with
documented allergy to penicillin.
The most prevalent capsular serotypes in our popula-
tion were III, V and Ia [20]. ST1, ST19 and ST23 were
the predominant clones, accounting for 28% of our iso-
lates. All three STs have been consistently reported to
be significantly associated with asymptomatic
colonization because of their limited invasive ability [14].
However, when it belongs to capsular serotype V, ST1
has been related to invasive disease, and a possible origin
from a bovine ancestor has been hypothesized, similar to
the case for hypervirulent clone ST17 [35]. Likewise,
ST23 was found in carriage and invasive isolates [36].
Clone ST17 was identified in only one strain.
We confirmed significantly higher rates of resistance
to macrolides and clindamycin associated with the gen-
etic background of ST1, belonging to clonal complex 1,
as previously described [27]. However, in contrast to
Lopes et al., who reported the association of ST1 and
capsular serotype Ib, we observed a relation to capsular
serotype V [27]. The association of ST1 and capsular
serotype V has also been described elsewhere [37].
Our study has limitations. Because of slow recruit-
ment, the study was terminated prior to reaching the
calculated target sample size, ending in a relatively small
study population. However, the number of participants
was comparable to (or even larger) than those in previ-
ous studies, and the GBS prevalence was similar to that
of a study that included 600 individuals [15, 25, 26]. We
only obtained vaginal and not recto-vaginal swabs, and
may have missed an unknown proportion of GBS colo-
nized individuals. However, we are convinced that the
potential difference between the two sampling methods
did not influence significantly the overall GBS
colonization rate in our study population. Eight GBS iso-
lates were lost for phenotypic and genotypic analysis
(Fig. 1). Given the lack of association between risk fac-
tors, resistance testing and serotype, it is unlikely that
the results of these eight lost GBS isolates would have
changed the overall findings.
Conclusions
The GBS vaginal colonization rate in women aged 60 or
more was 17%. The observed increase in invasive GBS
infections in elderly women may be for reasons other
than the colonization rate. We found no associations
with patient characteristics, comorbidities, menstrual
history, menopause or sexual activity. Twenty-two per-
cent of the isolates were not susceptible to clindamycin,
and this pattern was associated with ST1. The most fre-
quently found capsular serotypes were III and V. Our re-
sults indicate that the prevalence of colonization, the
antibiotic susceptibility and the molecular patterns are
similar in pregnant and elderly women.
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